Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 3Sarcoma 1Other hematologic neoplasm 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 27Lymphoma, Non-Hodgkin 11Lymphoma, B-Cell 9Hematologic Diseases 6Lymphoma, Mantle-Cell 5Leukemia, B-Cell 4Waldenstrom Macroglobulinemia 3Lymphoma, B-Cell, Marginal Zone 3Leukemia 3Lymphoma 2Leukemia, Lymphoid 2Syndrome 1Recurrence 1Multiple Myeloma 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Hematologic Neoplasms 1Dendritic Cell Sarcoma, Interdigitating 1Chromosome 17 deletion 1

Interventions

Cyclophosphamide 149Rituximab 104Peripheral Blood Stem Cell Transplantation 101fludarabine phosphate 100Filgrastim 72Mycophenolic Acid 67Cyclosporine 59Radiotherapy 58Whole-Body Irradiation 57Etoposide 55Tacrolimus 51Busulfan 50Antilymphocyte Serum 43Melphalan 41Methotrexate 37Cytarabine 27Cord Blood Stem Cell Transplantation 26fludarabine 25Bortezomib 24Methylprednisolone 23Carmustine 22sargramostim 21Flow Cytometry 19Dexamethasone 19Lenalidomide 18Granulocyte Colony-Stimulating Factor 18Vincristine 17Prednisone 17Bendamustine Hydrochloride 17aldesleukin 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, Follicular × pirtobrutinib × Other hematologic neoplasm × Clear all
NCT03740529 2026-01-27

A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL

Eli Lilly and Company

Phase 1/2 Completed
803 enrolled 2 FDA
LymphoidOther hematologic neoplasmSarcoma

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Dendritic Cell Sarcoma, Interdigitating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡